A GlaxoSmithKline spokesman confirmed Friday that US prosecutors are investigating the company for anti-bribery violations in China, as reported Fidelity.
According to a source, the US Department of Justice expanded a probe of GlaxoSmithKline's practices in other countries to include allegations of bribery in China.
Chinese authorities revealed in July that four GlaxoSmithKline executives were detained on allegations that the company funnelled up to 3 billion yuan in kickbacks to doctors and officials in the country.
US officials are investigating whether GlaxoSmithKline violated the Foreign Corrupt Practices act, which forbids companies based in the US or those whose stocks are listed on a US stock exchange from engaging in bribery
GlaxoSmithKline acknowledged that some of its employees in China may have engaged in bribery, but it denies that the company had any knowledge of the activity.
"Since the investigation in China began we have proactively reached out to relevant regulators," remarked GlaxoSmithKline spokesman David Mawdsley, adding "this includes the [US Department of Justice}, and we have been in an ongoing dialogue with them."